Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells $230,114.06 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 8,426 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total transaction of $230,114.06. Following the sale, the general counsel now owns 146,126 shares of the company’s stock, valued at approximately $3,990,701.06. The trade was a 5.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Phreesia Trading Up 2.3 %

Shares of PHR opened at $27.89 on Friday. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.16. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average price is $24.00 and its 200-day moving average price is $23.00. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -18.98 and a beta of 0.94.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.58) EPS. Sell-side analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Truist Financial increased their target price on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Friday, January 10th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. KeyCorp increased their price target on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, January 8th. Finally, Citigroup boosted their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.00.

Hedge Funds Weigh In On Phreesia

A number of institutional investors have recently added to or reduced their stakes in PHR. Deerfield Management Company L.P. Series C purchased a new stake in shares of Phreesia in the 2nd quarter worth about $4,078,000. Champlain Investment Partners LLC grew its holdings in Phreesia by 4.1% in the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock worth $57,062,000 after purchasing an additional 97,847 shares during the period. Sei Investments Co. increased its stake in shares of Phreesia by 135.3% during the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock valued at $3,505,000 after purchasing an additional 95,058 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Phreesia by 56.3% during the second quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock valued at $5,308,000 after purchasing an additional 90,215 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after purchasing an additional 88,517 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.